Icon

Pfizer, Roche join ADDPLAN DF Consortium

Monday, August 4, 2014 02:12 PM

Pfizer and Roche have joined the ADDPLAN DF Consortium. The consortium was founded in 2013 by Novartis, Janssen PharmaceuticalsEli Lilly and Aptiv Solutions, an Icon company, to lead the design and implementation of adaptive trials. The goal of the ADDPLAN DF Consortium is to develop methodologies and execution technologies that improve dose-selection, which remains a major barrier to resolving high failure rates in phase III trials.

More... »

WIRB Copernicus Group

Aptiv Solutions launches ADDPLAN DF 3.0

Wednesday, May 14, 2014 01:35 PM

Aptiv Solutions, an Icon company focused on the design and implementation of adaptive trials, has released ADDPLAN DF 3.0, which incorporates complex statistical methodologies to prevent under- and over-estimation of a therapeutic’s maximum target dose (MTD) during phase I dose escalation trials.

More... »


Icon completes acquisition of Aptiv Solutions

Thursday, May 8, 2014 01:15 PM

CRO Icon has completed its previously announced acquisition of Aptiv Solutions.

More... »

Icon appoints Hugh Brady to board of directors

Wednesday, April 30, 2014 03:11 PM

CRO Icon has appointed Dr. Hugh Brady as a non-executive director on the board of directors.

More... »

Icon’s Firecrest training recognized by TransCelerate BioPharma

Monday, April 14, 2014 10:13 AM

Icon,a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, has announced that its Firecrest training meets TransCelerate BioPharma’s minimum criteria for International Conference on Harmonization Good Clinical Practice (ICH/GCP) training.

More... »

Icon awarded best CRO at World Vaccines Congress 2014

Thursday, April 3, 2014 11:33 AM

Icon,a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, has been named Best Clinical Research Organization in the Vaccine Industry Excellence (ViE) Awards.

More... »

Icon acquires Aptiv Solutions to strengthen adaptive design capabilities

Monday, March 31, 2014 03:04 PM

Seeking to enhance its capabilities in the design and execution of portfolio-wide adaptive clinical trials for pharmaceutical, biotech and medical device companies, Icon has agreed to acquire Aptiv Solutions, a global services company focused on enhancing clinical trial decision-making, for $143.5 million in cash.

More... »

Report: pharmacovigilance market, service providers to reach $5B globally in 2019

Friday, February 28, 2014 12:02 PM

According to a new market report published by Transparency Market Research, the global pharmacovigilance market was valued at $2,147.3 million in 2012 and is estimated to reach a market worth $5,008.2 million in 2019, at a CAGR of 12.9% from 2013 to 2019.

More... »

Icon appoints Dariush Elahi head of metabolic research, early phase

Monday, January 20, 2014 01:20 AM

Global CRO Icon has appointed Dr. Dariush Elahi director of metabolic research. Based in Icon’s Clinical Pharmacology Unit in San Antonio, U.S., Elahi will lead Icon’s early phase glucose clamping programs globally, providing expert, scientific consultation to sponsors who are developing therapeutic agents to treat endocrine/metabolic disease.

More... »

Icon CEO Ciaran Murray elected ACRO chairman

Friday, January 17, 2014 11:36 AM

Icon , a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, has announced its chief executive, Ciaran Murray, has been elected 2014 chairman of the Association of Clinical Research Organizations (ACRO). Icon legal counsel, Diarmaid Cunningham, also has been elected as secretary of ACRO for a second term. 

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

August 25

Verizon Communications enters clinical trial space with technology, network, and cloud and data services

Sponsors look to the power of genomic profiling to screen, enroll patients in trials for targeted therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs